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I t is an honor and privilege to address the Baptist Health South Florida (BHSF) family with my inaugural 
communication as the newly appointed Corporate Vice 
President of Research.  As we all know, BHSF prides itself on 
providing high-quality, cost-effective, compassionate healthcare 
to improve the health and well-being of individuals in the 
communities we serve.  In fact, that’s part of our institution’s 
mission!  High-quality care is in large part accelerated by 
scientific discovery made possible through research.   
Because BHSF recognizes the importance and value of 
research as an essential component in the pathway to providing 
superior care to our community, we conducted an in-depth 
assessment of clinical research across the system.  Pursuant to 
the assessment, we set forth and have begun to implement a 
plan to reorganize our research programs and the supporting 
infrastructure.  The overarching goals of our revitalized approach 
to research across the enterprise includes: 
 Aligning research activities with the BHSF strategic plan; 
 Standardizing research administrative procedures across 
the enterprise; 
 Promoting safe, compliant, efficient, and fiscally 
responsible operational procedures; 
 Supporting our Graduate Medical Education programs;  
 Promoting innovation; and 
 Supporting our academic affiliations. 
Reorganization of the research enterprise is grounded on the 
foundation of local control with central standards.  Local control 
means that each entity conducting research is wholly 
responsible for development of its research vision and mission 
(aligned with the corporate vision), and then overseeing 
personnel that are required to perform research activities 
(research nurses, coordinators, etc.).  Central standards that 
support research include system-wide operational, compliance, 
and financial procedures that will be utilized by all BHSF entities 
engaged in the conduct of research.  
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“I love the journeys 




~Dries Van Noten~ 
Quote: Interview (2012) 
Cont’d on next page 
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All research, with the exception of oncology based research, will fall within the purview of the 
reorganized Center for Research. Oncology research in Miami will continue under the Miami 
Cancer Institute (MCI) Office of Clinical Research.  Initial steps to align the Lynn Cancer Institute 
(LCI) research program with MCI are underway.   
The Center for Research will provide centralized support for investigator-initiated protocol 
development, research financial administration, research grants, research compliance, human 
subject protections including the IRB, and will serve as the coordinating center for BHSF 
enterprise-wide research clinical operations.  In addition, the Center for Research will continue 












With the beginning of FY22, the following changes have been made: 
 Debbie Suarez will oversee research administration for the entire enterprise 
 Lara Arias will serve as the Director of the Office of Protocol Development (Investigator-
Initiated Research) for non-oncology studies. 
 Amy Starosciak’s role as Director of Outcomes Research changed and she now will 
focus on standardization of clinical operations inclusive of quality and education. 
 Amanda Coltes-Rojas and the IRB team transitioned into the Center for Research.  
Amanda will lead the Office of Research Integrity which includes the IRB and the 
research compliance program. 
 Katie Calienes has been promoted to Manager to lead the BHSF research grants 
program. 
 The clinical research teams that were housed in the Center for Research have been 
moved into their respective Centers of Excellence. 
Personally, I am very excited about the future state of research throughout BHSF.  We all 
recognize that it takes time to build and implement new programs but there is no doubt that we 
successfully will transition into a nationally recognized leader of clinical research. 
A reorganization of this scope required the assistance of so many and I want to thank BHSF 
Executive Leadership, especially Drs. Ziffer and Zinner for providing unyielding support over the 
past four months.  In addition, I would like to thank the Human Resources teams (Mayelin 
Maruri, Alicia Cuervo, and Tianne Macias), Finance (Janette Sanchez, Pete Mallias, and 
Angela McMillon), the Compensation team (Kurt Estill), and of course the amazing staff from 
both the Center for Research and the MCI Office of Clinical Research. 
—Scott Lipkin, DPM, Vice President for Research, BHSF and Chief Research Officer, MCI 
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I n the past 3 years I had definitely felt this way more than a few times.  Jumping into MCI can be dizzying and even more so when 
leaping into research.  In clinical trials we’re often encountering difficult 
and new situations and I think that’s why a lot of us are initially attracted 
to being in research. We are faced with new frontiers and new ways of 
doing things that force us into uncomfortable positions.  It has been an 
amazing experience to work with some very collaborative teams who’ve 
helped identify creative approaches to one of the most complex areas 
of clinical practice and helped me to better understand things I 
struggled with.  As a new program and a building program, we still have 
much to grow but we have already done so much.  From COVID-19 
treatments, to emergency compassionate use requests, to supporting 
Phase-1, master, and investigator-initiated protocols. 
I’m extremely proud of the MCI Investigational Drug Services team who continue to bring 
their highly-specialized skills to our patients. 
Thank you to all those who’ve helped me with a good helping 
of patience when I needed guidance for something I didn’t 
know about.  In my next role I’ll also be jumping to an area 
where I won’t know what I’m doing at first, but I can only hope 
that my new coworkers will have the same kind, pineapple-
spirit and gently let me know what I humbly don’t know.  
With warmest regards,   
Nicholas Chow, PharmD, BCOP  
(Soon to be FDA, Oncology Safety Reviewer) 
REFLECTIONS 
AN APPRECIATIVE FAREWELL FROM MCI’S IDS PHARMACY SUPERVISOR 
“Research is what 
I’m doing when I 
don’t know what 
I’m doing.” 
Wernher von Braun 
Quote: NYT interview (16-Dec-1957) 
 
NEW CEU PLATFORM 
Baptist Health Center for Research has partnered with with Association of Clinical 
Research Professionals (ACRP) to offer a competency platform with clinical research 
CEUs to our research staff.  The platform is powered by Pro-ficiency and offers over 
20 courses and 30 hours of content including informed consent and Good Clinical 
Practice simulations.  The rollout started primarily with research operations staff 
(Clinical Research Coordinators and Research Nurses) but we already are looking to 
expand the program to other research staff as well.  If you are a coordinator or 
research nurse and have not received login information, please contact your leader. 
—Amy K. Starosciak, Ph.D., Director of Research Operations  
& Quality Assurance, Center for Research 
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UNDERSTANDING THE RIGHT-TO-TRY ACT 
 
What is the Right-to-Try Act and How Does it Differ from Compassionate Use?  
P atients diagnosed with cancer have often tried all standard care available with little to no success; at this point, they might seek out experimental treatments but may 
be ineligible to participate in clinical trials. Fortunately, there are other pathways a patient 
can take to gain access to investigational treatments not yet approved by the Food and Drug 
Administration (FDA), such as the Expanded Access Program. This program allows 
individuals with immediate life-threatening conditions to have access to investigational 
drugs or devices free of charge, with the condition that the patient must obtain formal FDA 
approval before beginning treatment. Currently, Boca Raton Regional Hospital, Miami 
Cancer Institute, and Miami Cardiac & Vascular Institute have established processes for 
Expanded Access, but Center for Research is working to align those pathways and extend 
the process to the Baptist Health system. 
More recently, another pathway has come about, the Right-To-Try Act. Like the Expanded 
Access Program, the Right-To-Try Act allows patients with life-threatening conditions, who 
are unable to participate in clinical trials, access to certain unapproved treatments, but 
without formal FDA approval. To ensure safety, the investigational drug must have 
completed at least a Phase I clinical trial to establish an agent’s safety, with the expectation 
that the agent will continue to undergo further investigations. 
Although the Right-To-Try Act provides an expedited path requiring less documentation and 
reporting, without the FDA’s involvement, there is limited liability. Additionally, under the 
Right-To-Try Act, unless the manufacturer is willing to provide the investigational agent for 
free, the patient must pay for treatment out of pocket. Both the Expanded Access Program 
and the Right-To-Try Act bridge the gap between drug development and FDA approval, 
providing access to potentially life-saving treatment.  
— Kirsten Lechner, Pharmacy Student, Palm Beach Atlantic University 
References: 
Gabay M. RxLegal: A Rapid Review of Right-To-Try. Hosp Pharm. 2018;53(4):234-235. doi:10.1177/0018578718783992  
Congress.gov. S.204 Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017. 115th Congress (2017-2018). 
Accessed September 24, 2021, from https://www.congress.gov/bill/115th-congress/senate-bill/204.  
The Florida Senate. Bill 1052: Experimental Treatments for Terminal Conditions. Accessed September 27, 2021, from https://www.flsenate.gov/
Session/Bill/2015/1052   
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Continuing with our theme of research 
transformation, Baptist Health South Florida 
is implementing Florence eBinders 
(“Florence”) to streamline research 
operations and aid with regulatory 
compliance.  Benefits of using this system 
are as follows: 
Convenience: Because Florence is cloud-
based, it will be accessible from anywhere, 
eliminating the need to travel between sites 
to collect signatures, update documents, or 
complete paper-based logs. 
Compliance: Florence will be validated 
for 21 CFR Part 11 compliance and is 
HIPAA compliant. It includes key features 
such as robust access controls, compliant 
and easy to use eSignature workflows, and 
the ability to redact documents for PHI and 
view audit trails.    
Consistency:  The structure and name of 
binder sections, sub-sections, and document 
placeholders will be automatically set up 
using a pre-defined binder “blueprint” or 
template. This template will help ensure 
that binders are set up consistently and 
according to our SOPs. 
Tools: Florence has several tools to keep 
study teams on track. Examples include the 
ability to set expiration dates on documents, 
set up email reminders, and create and 
manage tasks.  Using the Global View, 
study teams can get a birds’ eye view of a 
binder, and can quickly see what’s still 
pending.  Because Florence has tools to 
archive older versions of documents, 
teams can be confident that they’re working 
with the correct version. 
Integration:  Florence will be integrated 
with the OnCore Clinical Trial Management 
System. The integration will drive the 
automatic creation of binders and enable 
staff access.  Binders also can be created 
directly in Florence. 
Who will use it: Initially, the Miami 
Cancer Institute, the Miami Neuroscience 
Institute, and departments supported by the 
Center for Research will use Florence.  
Members of the study teams who work with 
paper-based regulatory binders will perform 
similar functions in Florence. 
When will it be available?  Mid- to late-
November 2021. 
Want to learn more or interested in using 
Florence? Contact us! 
researchsystems@baptisthealth.net 
—Carrie Figueredo, MLIS, Manager of 
Library & Research Support Systems, 
Center for Research 
Florence eBinders 
COMING SOON!  
Photo by Viktor Talashuk on Unsplash  Photo from FlorenceEHC.com 
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New & Transferred Staff Updates 
Isabel Octaviano 
Zbeda, RN 
Clinical Trials Nurse 








Office of Clinical 
Research, MCI 






We have a number of research positions open across Baptist Health!  Are you looking 
for a new opportunity in research or know someone who is?  Below is a sample of 
what we have available.  Click here to see them all! 
Judyta Kociolek, RN 
Oncology Research 
Nurse 
Center for Research, 
LCI, BRRH 
 Oncology Research RN—BRRH and MCI 
 Research Compliance —Center for Research 
 Dir Research Concept & Protocol Dev—MCI 
 Tissue Acquisition Spc—Center for Research 
 Nurse Scientist—Nursing & Health Sciences 
 Research Finance Spc—MCI and Center for 
Research 
 Multiple CRC levels—MCI 
 Research Monitor—MCI 
 Dir Biorepository & Protocol Support—MCI  
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Explore some of our recent publications! 
New Article Alcove 
Anolik RA, Nelson JA, Rosen EB, et al. (2021) Immediate dental implant 
placement in the oncologic setting: A conceptual framework.  Plast Reconstr 
Surg Glob Open 9(9):33671.  Find it here! 
Filatov A, Alvarez J, Seibert J, Swerdloff M (2021)  Management of Pediatric 
Strokes With Alteplase (Tissue Plasminogen Activator). Cureus  13
(8):e17088.  Find it here! 
Fleming JL, Pugh SL, Fisher BJ, ...Mehta MP, Chakravarti A (2021) Long-
term report of a comprehensive molecular and genomic analysis in NRG 
Oncology/RTOG 0424: A phase II study of radiation and temozolomide in 
high risk grade II glioma.  JCO Precis Oncol 5:PO.21.00112.  Find it here! 
Gelb DJ, Kraakevik J, Safdieh JE, ...Odia Y, et al. (in press) Contemporary 
neuroscience core curriculum for medical schools.  Neurology  Find it here! 
Greten TF, Abou-Alfa GK, Cheng A-L, ...Lencioni R, et al. (2021) Society for 
Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of 
hepatocellular carcinoma.  J Immunother Cancer 9(9):e002794.  Find it here! 
Jiam NT, David AP, Formeister EJ, ...McDermott MW, El-Sayed IH (2021) Presentation and management of 
post-operative cerebrospinal fluid leaks after sphenoclival 
expanded endonasal surgery: A single institution experience.  
J Clin Neurosci 91:13-19.  Find it here! 
Kittipibul V, Blumer V, Hernandez GA, ...Chaparro S, Agarwal 
R (2021) Pre-operative atrial fibrillation and early right 
ventricular failure after left ventricular assist device 
implantation: a systematic review and meta-analysis.  Am 
Heart J 239:120-128.  Find it here! 
Lauko A, Kotecha R...Ahluwalia MS (2021) Impact of KRAS 
mutation status on the efficacy of immunotherapy in lung 
cancer brain metastases.  Sci Rep 11(1):18174.  Find it here! 
Lazaro LE, Lim DP, Nelson TJ, et al. (2021) Proximal 
overresection during femoral osteochondroplasty negatively 
affects distractive stability of the hip joint: A cadaver study.  
Am J Sports Med 49(11):2977-2983.  Find it here! 
Martin Diaz C, Guizan Corrales E, Belnap S, Kline J, 
Gopalani R, Marrero S, De Los Rios La Rosa F (2021) 
Anticoagulation after ischemic stroke or transient ischemic 
attack (TIA) in the time of direct oral anticoagulation (DOAC) 
and thrombectomy.  Cureus 13(8):e17392.  Find it here! 
Xian Z, Saxena A, Javed Z, et al. (2021) COVID-19-related 
state-wise racial and ethnic disparities across the USA: an 
observational study based on publicly available data from The 
COVID Tracking Project.  BMJ Open 11(6):e048006.  Find it 
here! 
REMINDER:  Backissues of the Research Matters 
newsletter can be found on the Scholarly Commons in 
addition to all our published research.  Find them here! 
Photo by Henry Be on Unsplash 
Explore more publications from the 
Baptist Health Institutional Repository 
Center for Advanced Analytics 
Center for Research 
Christine E. Lynn Heart & Vascular 
Institute 
Christine E. Lynn Women's Health & 
Wellness Institute 
Eugene M. & Christine E. Lynn Cancer 
Institute 
Marcus Neuroscience Institute 
Miami Cancer Institute 
Miami Cardiac & Vascular Institute 
Miami Neuroscience Institute 
Miami Orthopedics & Sports 
Medicine Institute 
Did we miss your publication?  
Please send it to: library@baptisthealth.net 
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Tuesdays 12:00 to 1:00 pm 
Invite was sent out to Research Operations & 
Regulatory teams. Certificates provided. 
Because of the COVID-19 pandemic, we will be 
doing Zoom™ meetings only until further notice. 
Click here or go to baptisthealth.zoom.us  
Meeting ID: 958 8490 1869 
Password: 861787 
Date Topic 
Tuesday, November 9th 
Appraisal of Statistical Methods in Research – Part 2 , Live with Emir 
Emir Veledar, Ph.D. 
Tuesday, December 14th Participant Recruitment 
by Pharmacy, Nursing & Clinical Research Organizations 
UPCOMING CONFERENCES 
ANCC Magnet & Pathway—November 11-13, 2021, Atlanta, GA  
https://www.magnetcon.org/ 
Onsemble Spring—March 29-April 1, 2022, Savannah, GA 
https://onsemble.net/conference/ 
ACRP—April 22-25, 2022, Orlando, FL 
https://2021.acrpnet.org/acrp-2022-save-the-date 
MAGI Spring Conference—May 1-4, 2022, Boston, MA 
https://www.magiworld.org/FutureConferences 
SOCRA—September 16-18, 2022, Orlando, FL 
https://www.socra.org/annual-conference/future-annual-conference-dates/ 
Onsemble Fall—September 27-30, 2022, Madison, WI 
https://onsemble.net/conference/ 
MAGI Fall Conference—October 23-26, 2022, Las Vegas, NV 
https://www.magiworld.org/FutureConferences 
Nursing World Conference—October 27-29, 2022, Orlando, FL 
https://nursingworldconference.com/ 
We need your help to plan the next 
year of Lunch & Learn topics!  Scan 
this QR code or click here to take a 
short Needs Assessment Survey.  
The topics with the most responses 




To serve as a 
research hub for 
elevating care 
through discovery for 
the diverse 
community we serve 
by using a shared 




collaborative intellect.  
 
VISION 
In alignment with the 
strategic goals of 
Baptist Health South 
Florida, and within the 
context of a 
sustainable business 




knowledge with the 
goals of providing 
continued excellence 
in patient care for the 
diverse multicultural 
community of South 
Florida. 
The FDAAA of 2007, Section 801 requires responsible parties (RP) of 
applicable clinical trials (ACTs) to register the study and report results 
to ClinicalTrials.gov (CT.gov).  
The FDA may issue a Pre-Notice of Non-Compliance Letter for any 
non-compliant ACTs providing the RP 30 days to become compliant. 
If unresolved, the FDA may issue a public Notice of Non-Compliance, 
FDAAA 801 Violation, providing 30 days to correct the non-
compliance or face financial penalties. In 2021, the FDA has 
submitted its first, second, and third public Notice of Non-compliance 
to institutions and an investigator.  
What does that mean for you? This is the time to review the status of 
your ACT in ClinicalTrials.gov, the listed RP, and the listed address to 
ensure all information is accurate and up-to-date. Please be aware 
that any communication from the FDA regarding CT.gov non-
compliance will be sent by mail to RP’s listed address. Please 
promptly contact Research Compliance should you or the RP receive 
any Pre-Notice or Notice of Non-Compliance.  
Research Compliance will soon provide training sessions and 
webinars regarding CT.gov and the upcoming 
modernization of the CT.gov system which will 
enhance the user experience. 
Do you have any questions or topics you would like 
for us to cover regarding conflicts of interest, 
compliance review, or billing compliance process? If 
so, contact us directly for all Research Compliance 
matters at:  ResearchCompliance@baptisthealth.net!  
—Heather Osorio, Research Compliance Supervisor 
Research Compliance Corner 
To contribute to this newsletter, please contact Dr. Amy Starosciak at amyst@baptisthealth.net or x79546. 
UPCOMING IRB DATES 
BHSF IRB 
Full Board Committee Meeting: Tuesday, November 23rd  
Submission Deadline for December Meeting: Monday, November 22nd 
MCI IRB 
Full Board Committee Meeting: Monday, December 6th 
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